- Home
- VATE
VATE
INNOVATE Corp.
as 04-18-2025 1:44pm EST
| Founded: | 1994 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | N/A | IPO Year: | 1996 |
| Target Price: | N/A | AVG Volume (30 days): | 50.7K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.25 - $13.79 | Next Earning Date: | 05-06-2025 |
| Revenue: | $1,107,100,000 | Revenue Growth: | -22.20% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest INNOVATE Corp. News
VATE Breaking Stock News: Dive into VATE Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
INNOVATE Corp. to Report First Quarter 2025 Results on May 6th
Simply Wall St.
17 days ago
INNOVATE Full Year 2024 Earnings: US$3.35 loss per share (vs US$4.81 loss in FY 2023)
GlobeNewswire
19 days ago
INNOVATE Corp. Announces Fourth Quarter and Full Year 2024 Results
Simply Wall St.
a month ago
INNOVATE Insider Ups Holding By 25% During Year
GlobeNewswire
2 months ago
INNOVATE Corp. to Report Fourth Quarter and Full Year 2024 Results on March 31st
GlobeNewswire
2 months ago
MediBeacon® Transdermal GFR System receives device approval in China
Simply Wall St.
3 months ago
INNOVATE (NYSE:VATE) shareholders are up 114% this past week, but still in the red over the last three years
GuruFocus.com
3 months ago
Innovate Shares Surge 63% Following FDA Approval of MediBeacon's Kidney Function Assessment System
Compare VATE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VATE INNOVATE Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.